- Ongoing clinical trial is the first ever to
combine targeted radiotherapy conditioning, Iomab-ACT, with
CAR-T cell therapy to achieve lymphodepletion along with reduction
of cytokine release syndrome and neurotoxicity
- Targeted conditioning directed at CD45 has the
potential to significantly expand the market opportunity for
cellular and gene therapies in multiple indications by eliminating
or reducing the need for non-targeted chemotherapy conditioning
NEW
YORK, Oct. 4, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
announced the National Institutes of Health (NIH) awarded Actinium
a Small Business Technology Transfer grant extension to support its
clinical collaboration with Memorial Sloan Kettering Cancer Center
(MSK) to study Iomab-ACT, Actinium's CD45-targeting
radiotherapeutic, for targeted conditioning to achieve
lymphodepletion therapy along with the reduction of cytokine
release syndrome and neurotoxicity prior to administration of a
CD19-targeted CAR-T cell therapy developed at MSK.
"Iomab-ACT has the potential to significantly improve the
patient journey and increase patient access to revolutionary
therapies like cellular and gene therapies by eliminating or
reducing the need for non-targeted chemotherapy," said Sandesh Seth, Chairman and Chief Executive
Officer. "We are grateful to have been awarded the extension of
this NIH grant, which will fund the advancement of this important
clinical collaboration."
Iomab-ACT is a next-generation, CD45-targeted conditioning agent
intended to enable either lymphodepletion or reduced intensity
conditioning prior to CAR-T and gene therapies with
multi-indication potential. Iomab-ACT has the potential to reduce
toxicities and improve patient outcomes when paired with MSK's CD19
CAR-T cell therapy in difficult to treat relapsed or refractory
B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B
cell lymphoma (DLBCL). This grant will advance the ongoing study of
Iomab-ACT for patients with relapsed or refractory B-ALL or
DLBCL.
About Actinium
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other blood
cancers and next generation conditioning candidate Iomab-ACT to
improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma for
solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid
tumors, and several internal programs in solid tumors. Actinium
holds more than 200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-announces-nih-grant-extension-to-advance-clinical-development-of-next-generation-cd45-targeted-conditioning-agent-iomab-act-with-memorial-sloan-ketterings-car-t-cell-therapy-301946619.html
SOURCE Actinium Pharmaceuticals, Inc.